Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.

Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1289-1301. doi: 10.1007/s00280-019-03960-w. Epub 2019 Sep 23.

PMID:
31549216
2.

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS.

Gynecol Oncol. 2017 May;145(2):236-242. doi: 10.1016/j.ygyno.2017.03.013. Epub 2017 Mar 22.

3.

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.

Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM.

Clin Cancer Res. 2016 Jun 15;22(12):2855-64. doi: 10.1158/1078-0432.CCR-15-2137. Epub 2016 Jan 22.

4.

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.

Lee JJ, Seraj J, Yoshida K, Mizuguchi H, Strychor S, Fiejdasz J, Faulkner T, Parise RA, Fawcett P, Pollice L, Mason S, Hague J, Croft M, Nugteren J, Tedder C, Sun W, Chu E, Beumer JH.

Cancer Chemother Pharmacol. 2016 Mar;77(3):515-26. doi: 10.1007/s00280-016-2965-2. Epub 2016 Jan 19.

5.

A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.

Eads JR, Beumer JH, Negrea L, Holleran JL, Strychor S, Meropol NJ.

Cancer Chemother Pharmacol. 2016 Feb;77(2):333-8. doi: 10.1007/s00280-015-2939-9. Epub 2015 Dec 21.

6.

Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews.

Eiseman JL, Beumer JH, Rigatti LH, Strychor S, Meyers K, Dienel S, Horn CC.

Cancer Chemother Pharmacol. 2015 Jan;75(1):143-52. doi: 10.1007/s00280-014-2623-5. Epub 2014 Nov 15.

7.

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.

Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY.

Cancer Med. 2014 Dec;3(6):1579-94. doi: 10.1002/cam4.317. Epub 2014 Aug 13.

8.

Clove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis.

Liu H, Schmitz JC, Wei J, Cao S, Beumer JH, Strychor S, Cheng L, Liu M, Wang C, Wu N, Zhao X, Zhang Y, Liao J, Chu E, Lin X.

Oncol Res. 2014;21(5):247-59. doi: 10.3727/096504014X13946388748910.

9.

A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer.

Magge D, Zureikat AH, Bartlett DL, Holtzman MP, Choudry HA, Beumer JH, Pingpank JF, Holleran JL, Strychor S, Cunningham DE, Jones HL, Zeh HJ 3rd.

Ann Surg Oncol. 2013 Jul;20(7):2180-7. doi: 10.1245/s10434-013-2960-3. Epub 2013 Apr 11.

10.

Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.

Wu H, Ramanathan RK, Zamboni BA, Strychor S, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Maruca LJ, Bang YJ, Zamboni WC.

Int J Nanomedicine. 2012;7:5555-64. doi: 10.2147/IJN.S35751. Epub 2012 Oct 19.

11.

A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.

Pishvaian MJ, Slack R, Koh EY, Beumer JH, Hartley ML, Cotarla I, Deeken J, He AR, Hwang J, Malik S, Firozvi K, Liu M, Elston B, Strychor S, Egorin MJ, Marshall JL.

Cancer Chemother Pharmacol. 2012 Dec;70(6):843-53. doi: 10.1007/s00280-012-1969-9. Epub 2012 Sep 27.

12.

Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.

Wu H, Ramanathan RK, Zamboni BA, Strychor S, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Maruca LJ, Bang YJ, Zamboni WC.

J Clin Pharmacol. 2012 Feb;52(2):180-94. doi: 10.1177/0091270010394851.

PMID:
21233302
13.

Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.

Zamboni WC, Maruca LJ, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, Kim J, Bang Y, Lee H, Friedland DM, Stoller RG, Belani CP, Ramanathan RK.

J Liposome Res. 2011 Jun;21(2):158-65. doi: 10.3109/08982104.2010.496085. Epub 2010 Jul 14.

PMID:
20626314
14.

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

Ramalingam SS, Harvey RD, Saba N, Owonikoko TK, Kauh J, Shin DM, Sun SY, Strychor S, Tighiouart M, Egorin MJ, Fu H, Khuri FR.

Cancer. 2010 Aug 15;116(16):3903-9. doi: 10.1002/cncr.25264.

15.

Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.

Zamboni WC, Eiseman JL, Strychor S, Rice PM, Joseph E, Zamboni BA, Donnelly MK, Shurer J, Parise RA, Tonda ME, Yu NY, Basse PH.

J Liposome Res. 2011 Mar;21(1):70-80. doi: 10.3109/08982101003754385. Epub 2010 Jun 9.

PMID:
20528623
16.

Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.

Zamboni WC, Strychor S, Maruca L, Ramalingam S, Zamboni BA, Wu H, Friedland DM, Edwards RP, Stoller RG, Belani CP, Ramanathan RK.

Clin Pharmacol Ther. 2009 Nov;86(5):519-26. doi: 10.1038/clpt.2009.141. Epub 2009 Aug 12.

PMID:
19675541
17.

Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.

Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, Maruca L, Zamboni BA, Belani CP, Ramanathan RK.

Clin Cancer Res. 2009 Feb 15;15(4):1466-72. doi: 10.1158/1078-0432.CCR-08-1405. Epub 2009 Feb 3. Erratum in: Clin Cancer Res. 2009 Apr 15;15(8):2949-50.

18.

Drug-virus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model.

Wonganan P, Zamboni WC, Strychor S, Dekker JD, Croyle MA.

Cancer Gene Ther. 2009 May;16(5):405-14. doi: 10.1038/cgt.2008.99. Epub 2008 Dec 26.

19.

Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice.

Zamboni WC, Jung LL, Strychor S, Joseph E, Zamboni BA, Fetterman SA, Sidone BJ, Burke TG, Curran DP, Eiseman JL.

Invest New Drugs. 2008 Oct;26(5):399-406. doi: 10.1007/s10637-007-9109-9. Epub 2008 Feb 2.

PMID:
18246299
20.

Expression and activity of taxane-metabolizing enzymes in ovarian tumors.

DeLoia JA, Zamboni WC, Jones JM, Strychor S, Kelley JL, Gallion HH.

Gynecol Oncol. 2008 Feb;108(2):355-60. Epub 2007 Dec 11.

PMID:
18063021
21.

Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.

Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engbers C, Eiseman JL.

Clin Cancer Res. 2007 Dec 1;13(23):7217-23.

22.

Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.

Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC.

Mol Pharmacol. 2008 Mar;73(3):627-38. Epub 2007 Nov 19.

PMID:
18025070
23.

Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.

Zamboni WC, Strychor S, Joseph E, Parise RA, Egorin MJ, Eiseman JL.

Cancer Chemother Pharmacol. 2008 Aug;62(3):417-26. Epub 2007 Oct 24.

PMID:
17957368
24.

Endothelin receptor A blockade enhances taxane effects in prostate cancer.

Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, Strychor SA, Nelson JB, Pflug BR.

Neoplasia. 2006 Sep;8(9):725-32.

25.

Pharmacokinetics after endovascular lung perfusion with Cisplatin.

Brown DB, Cai SR, Fundakowski CE, Zamboni WC, Strychor S, McLeod HL.

J Vasc Interv Radiol. 2006 May;17(5):883-8.

PMID:
16687755
26.

Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.

Zamboni WC, Ramanathan RK, McLeod HL, Mani S, Potter DM, Strychor S, Maruca LJ, King CR, Jung LL, Parise RA, Egorin MJ, Davis TA, Marsh S.

Invest New Drugs. 2006 Sep;24(5):393-401.

PMID:
16505951
27.

Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.

Zamboni WC, Goel S, Iqbal T, Parise RA, Strychor S, Repinski TV, Egorin MJ, Mani S.

Cancer Chemother Pharmacol. 2006 May;57(5):631-9. Epub 2005 Oct 5.

PMID:
16205924
28.

Control-relevant modeling of the antitumor effects of 9-nitrocamptothecin in SCID mice bearing HT29 human colon xenografts.

Harrold JM, Eiseman JL, Joseph E, Strychor S, Zamboni WC, Parker RS.

J Pharmacokinet Pharmacodyn. 2005 Feb;32(1):65-83.

PMID:
16205839
29.

Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.

Fakih MG, Creaven PJ, Ramnath N, Trump D, Javle M, Strychor S, Repinski TV, Zamboni BA, Schwarz JK, French RA, Zamboni WC.

Clin Cancer Res. 2005 Aug 15;11(16):5942-9.

30.

Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.

Zamboni WC, Jung LL, Egorin MJ, Hamburger DR, Joseph E, Jin R, Strychor S, Ramanathan RK, Eiseman JL.

Clin Cancer Res. 2005 Jul 1;11(13):4867-74.

31.

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.

Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko S, Zamboni WC.

Cancer Chemother Pharmacol. 2005 Apr;55(4):354-360. doi: 10.1007/s00280-004-0909-8. Epub 2004 Oct 27.

PMID:
15723261
32.

Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.

Jung LL, Ramanathan RK, Egorin MJ, Jin R, Belani CP, Potter DM, Strychor S, Trump DL, Walko C, Fakih M, Zamboni WC.

Cancer Chemother Pharmacol. 2004 Dec;54(6):487-96. Epub 2004 Aug 18.

PMID:
15322760
33.

Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.

Zamboni WC, Jung LL, Egorin MJ, Potter DM, Friedland DM, Belani CP, Agarwala SS, Wong MM, Fakih M, Trump DL, Jin R, Strychor S, Vozniak M, Troetschel M, Ramanathan RK.

Clin Cancer Res. 2004 Aug 1;10(15):5058-64.

35.

Possible enzymatic causes for elevated phosphomonoesters in Alzheimer's disease brain tissue.

Kanfer JN, Pettegrew JW, Moossy J, McCartney DG, Bin Q, Strychor S, McKeag DW.

Ann N Y Acad Sci. 1991;640:118-21. No abstract available.

PMID:
1663713
36.

Changes in brain energy and phospholipid metabolism during development and aging in the Fischer 344 rat.

Pettegrew JW, Panchalingam K, Withers G, McKeag D, Strychor S.

J Neuropathol Exp Neurol. 1990 May;49(3):237-49.

PMID:
2335783
37.
38.

The effect of lithium on the membrane molecular dynamics of normal human erythrocytes.

Pettegrew JW, Short JW, Woessner RD, Strychor S, McKeag DW, Armstrong J, Minshew NJ, Rush AJ.

Biol Psychiatry. 1987 Jul;22(7):857-71.

PMID:
3111554

Supplemental Content

Loading ...
Support Center